Modular Medical MODD
NASDAQ MODD
$2.08 +0.08 (+4.00%)
At close: Oct 1, 2026 · 4:00 PM EDT

Modular Medical (MODD) Interest Coverage Ratio (2020 - 2022)

Updated

Modular Medical's Interest Coverage Ratio was -7.36 in fiscal Q4 2022 (quarter ended Mar 31, 2022), compared with -40.39 a year earlier.

Analysis

Modular Medical (MODD) Interest Coverage Ratio (2020 - 2022) Analysis & Trends

For FY2022 (ended Mar 31, 2022), Interest Coverage Ratio at Modular Medical came in at -5.42.

  • In earlier fiscal years, Interest Coverage Ratio was -184.38 in FY2021.
  • Quarterly Interest Coverage Ratio has moved between -602.44 (fiscal Q3 2021) and -3.79 (fiscal Q3 2022) over five years.
  • Per Business Quant data, MODD's Interest Coverage Ratio in the three fiscal quarters before Q4 2022 was -3.79 (Q3 2022), -5.39 (Q2 2022) and -6.63 (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Thermo Fisher Scientific 249.71 Bn 228.86 Bn 4.88 Bn 5.20
2 Abbott Laboratories 171.00 Bn 142.08 Bn 7.27 Bn 4.82
3 Danaher 155.79 Bn 139.61 Bn 3.61 Bn 10.53
4 Intuitive Surgical 143.91 Bn 123.46 Bn 1.96 Bn -
5 Medtronic 110.42 Bn 76.29 Bn 6.34 Bn 9.48
6 Stryker 105.71 Bn 91.82 Bn 4.50 Bn 11.77
7 Boston Scientific 63.26 Bn 58.27 Bn 3.85 Bn 12.27
8 Edwards Lifesciences 49.80 Bn 33.91 Bn 1.35 Bn -
9 Becton Dickinson 48.78 Bn 45.93 Bn 2.32 Bn 5.02
10 Modular Medical 11.14 Mn -7.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 -7.36
Dec 31, 2021 -3.79
Sep 30, 2021 -5.39
Jun 30, 2021 -6.63
Mar 31, 2021 -40.39
Dec 31, 2020 -602.44
Sep 30, 2020 -464.79
API Access

Modular Medical Interest Coverage Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-coverage-ratio&ticker=MODD&period=max&api_key=YOUR_API_KEY